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Summary
 
The HIV-1 virion-associated accessory protein Vpr affects both viral replication and cellular
transcription, proliferation, and differentiation. We report that Vpr enhances the activity of
glucocorticoids in lymphoid and muscle-derived cell lines by interacting directly with the glu-
cocorticoid receptor and general transcription factors, acting as a coactivator. Vpr contains the
signature motif LXXLL also present in cellular nuclear receptor coactivators, such as steroid re-
ceptor coactivator 1 and p300/CREB-binding protein, which mediates their interaction with
the glucocorticoid and other nuclear hormone receptors. A mutant Vpr molecule with disrup-
tion of this coactivator signature motif lost its ability to influence transcription of glucocorti-
coid-responsive genes and became a dominant-negative inhibitor of Vpr, possibly by retaining
its general transcription factor–binding activities. The glucocorticoid coactivator activity of Vpr
may contribute to increased tissue glucocorticoid sensitivity in the absence of hypercortisolism
and to the pathogenesis of AIDS.
Key words: nuclear receptors • AIDS • mouse mammary tumor virus • p300/CBP • steroid 
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T
 
he HIV-1 protein Vpr, a 96–amino acid virion-asso-
ciated accessory protein, has multiple functions (for
reviews, see references 1–4). Vpr enhances the replication of
HIV-1 virus in lymphocyte- and monocyte-derived cell lines
(5), is a weak transcriptional activator of several viral promot-
ers (6), causes host cell arrest in the G2/M phase of the cell
cycle (7–10), and induces terminal differentiation in some cell
lines (11). Vpr has been proposed to increase the translocation
of the HIV-1 preintegration complex into the nucleus, and
promotes efficient infection of nondividing macrophages
(12–15). Vpr was also reported to bind to a host 41-kD cyto-
solic Vpr interacting protein (Rip-1) and to associate with the
activated glucocorticoid receptor (GR)
 
1
 
 (16).
Since Vpr has been shown to circulate at detectable lev-
els in HIV-1–infected individuals, its effects may be ex-
tended to cells not infected by HIV-1 (17, 18). To explore
the potential involvement of Vpr in the pathogenesis of
AIDS, we examined the effect of Vpr on glucocorticoid-
responsive promoters and the interactions of Vpr with GR
and components of the GR-induced transcription complex
in lymphoid and rhabdomyosarcoma cell lines. We show
that Vpr is a virus-encoded coactivator of the GR, suggest-
ing that it may contribute to the development of symptoms
in patients with AIDS such as muscle wasting in the ab-
sence of increased glucocorticoid levels.
Glucocorticoids play major roles in maintaining resting
and stress-related homeostasis (19) and also exert antiinflam-
matory and immunosuppressive effects, which have made
them invaluable therapeutic agents in numerous diseases
 
(20).
 
 
 
Host tissue sensitivity to glucocorticoids may be altered
in several disease states, becoming one of the determinants of
disease outcome; both glucocorticoid hypersensitivity and
resistance have been reported (21). Glucocorticoid hypersen-
sitivity could be involved in the immunosuppression and
myopathy and muscle wasting observed in patients with
AIDS, even in the presence of normal plasma cortisol con-
centrations. Glucocorticoids exert their ubiquitous and
 
1
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pleiotropic effects through the GR, a ligand-dependent tran-
scription factor. Binding of the hormone to the receptor
causes it to dissociate from a heterooligomer of heat shock
proteins and to translocate into the nucleus, where it binds as
a homodimer to specific DNA enhancer elements, the glu-
cocorticoid response elements (GREs), or to other transcrip-
tion factors, such as AP-1 and nuclear factor (NF)-
 
k
 
B (22).
Several host coactivators of the GR have been described
that directly interact with the GR and components of the
transcription initiation complex to enhance the glucocorti-
coid signal to the transcription machinery (23, 24). Differ-
ent signal transduction systems share several of these newly
described coactivators, which may act not only in a syner-
gistic but also in an inhibitory fashion (25–27). It recently
became known that some coactivators possess histone
acetyltransferase activity, which helps loosen promoter
DNA from the tightly bound histone octamers by acetylat-
ing the free NH
 
2
 
 termini of lysine residues, facilitating the
access of components of the transcriptional initiation com-
plex to the promoter region (28–30). Here we show that
Vpr enhances the activation of a glucocorticoid-inducible
gene. We studied the mechanism of this effect and espe-
cially the interactions of Vpr with other components of the
transcription machinery. It was determined that Vpr inter-
acts directly with components of the RNA polymerase ho-
loenzyme and contributes to the formation of a large com-
plex competent for transcription.
 
Materials and Methods
 
Plasmids.
 
The pCDNA3-VPR and pGEX-4T3-VPR vec-
tors for expression of Vpr and GST-Vpr, respectively, were con-
structed using PCR-amplified Vpr sequence in pNLA1 (a gift
from Dr. K. Strebel, National Institutes of Health, Bethesda,
MD), which contains the full coding sequence of the wild-type
Vpr (31). The plasmids used were pCDNA3 (Invitrogen) and
PGEX-4T3 (Amersham Pharmacia Biotech), respectively. The
pCMV-FLAG-VPR and pCMV-FLAG-VPR(36–96) vectors were
generated by in-frame insertion of PCR-amplified Vpr cDNA
corresponding to amino acids 1–96 or 36–96 between the HindIII
and XbaI sites of pFLAG-CMV-2 (Eastman Kodak Co.). These
plasmids express Vpr fragments tagged at the NH
 
2
 
 terminus by
the FLAG epitope under the control of the CMV promoter. The
64 leucine to alanine–substituted mutant Vpr cDNAs were pre-
pared by PCR-assisted in vitro mutagenesis of the Vpr expression
vectors and named pCDNA3-VPRL64A, PGEX-4T3-VPRL64A,
and pCMV-FLAG-VPRL64A, respectively. Similarly, a vector
expressing Vpr with an arginine to alanine substitution at position
80 was named pCDNA3-VPRR80A. For the yeast two hybrid
assay, DNA-binding LexA fusion vector pEG202, B42-activation
domain fusion vector pJG4-5, and 
 
lacZ
 
 reporter plasmid pSH18-
34 were used (32). Plasmids LexA-Vpr and LexA-Tat express
Vpr or Tat fused to LexA DNA-binding domain, respectively
(33). LexA-VprL64A and LexA-VprR80A expression vectors were
constructed by PCR-assisted in vitro mutagenesis. The full-
length human (h)GR
 
a
 
 protein fused to B42-activation domain
expression vector was constructed by in-frame insertion of hu-
man GR
 
a
 
 cDNA into pJG4-5 (pJG45-GR
 
a
 
). The other plas-
mids used were as follows: pRc/RSV, pCR3.1, and pHook™-1
(Invitrogen); pSV40-
 
b
 
-Gal (Promega Corp.); 
 
b
 
-actin-luc, con-
taining 
 
2
 
472 to 
 
1
 
49 of human 
 
b
 
-actin promoter, pRShGR
 
a
 
and pGR107, containing the full-length coding region of hGR
 
a
 
,
and pRS-erbA
 
2
 
1
 
, containing a thyroid receptor cDNA in inverse
orientation but otherwise similar to pRShGR
 
a
 
 (all gifts from Dr.
R. Evans, Salk Institute, La Jolla, CA); pF25-GFP-hGR
 
a
 
, ex-
pressing green fluorescent protein (GFP) tagged at the NH
 
2
 
 ter-
minus of hGR
 
a
 
; pSVLPRA, containing the full-length coding
region of human progesterone receptor A (a gift from S.S.
Simons, Jr., National Institutes of Health); pRc/RSV-CREB341,
containing the full-length coding region of cAMP-responsive ele-
ment binding protein (CREB); RSV-PKA, which expresses the
constitutive active form of protein kinase A (PKA); p(
 
2
 
71)SRIF-
CAT, containing nucleotides 
 
2
 
71 to 
 
1
 
53 of rat somatostatin 5
 
9
 
flanking region (all gifts from Dr. R.H. Goodman, Vollum Insti-
tute, Portland, OR); CMV
 
b
 
-p300-CHA expression vector (a gift
from Dr. D. Livingston, Dana-Farber Cancer Institute, Boston,
MA); pCR-SRC-1a (a gift from Dr. B.W. O’Malley, Baylor Col-
lege of Medicine, Houston, TX); HE0, containing the full-length
coding region of human estrogen receptor 
 
a
 
 (a gift from Dr. P.
Chambon, University of Strasbourg, Strasbourg, France); pRSV-
 
b
 
-Gal and ERE-tk-luc, containing synthetic vitellogenin A2 ERE
sequence from 
 
2
 
336 to 
 
2
 
310 (gifts from Dr. J. Segars, National
Institutes of Health), pMMTV-luc (a gift from Dr. G. Hager, Na-
tional Institutes of Health), pHH-luc and pM-luc (American Type
Cell Collection), containing either full-length MMTV-LTR,
 
2
 
223 to 
 
1
 
105, or 
 
2
 
109 to 
 
1
 
105 of the MMTV-LTR, respec-
tively; and the synthetic GRE-containing plasmids, pGRE
 
2
 
-NF1-
E1B-CAT, pNF1-E1B-CAT, pGRE
 
2
 
-E1B-CAT, and pE1B-CAT
(gifts from Dr. J.A. Cidlowski, National Institutes of Health, Re-
search Triangle Park, NC).
 
Cell Transfections.
 
A204, HS729, and CV-1 cells were trans-
fected using lipofectin (Life Technologies); CEM and Jurkat cells
were transfected using electroporation (960 
 
m
 
F, 250 mV [34]).
The cells were treated with dexamethasone 24 h after transfec-
tion, and cell lysates were collected after a 24-h incubation with
the steroid. Luciferase activity, chloramphenicol acetyltransferase
(CAT) activity, and protein concentrations were determined as
described (35–37). All measurements of the reporter gene activity
were conducted in triplicate transfections and averaged. Cells
from the same transfection were used with and without dexa-
methasone whenever the effects of the steroid were studied.
 
Magnetic Cell Sorting and Immunoblots for the GR and Vpr.
 
The transfection-positive cells (0.5–1 
 
3 
 
10
 
7
 
 cells) were enriched
by the pHook™-1 plasmid method following the company’s rec-
ommendations, and homogenized and centrifuged at 300 
 
g
 
 for 5
min in Taps buffer (25 mM Taps [pH 8.0], 2 mM dithiothreitol,
Complete™ tablets 1 Tab/50 ml [Boehringer Mannheim], 10%
glycerol). The supernatants were used in Western blot analyses,
with affinity-purified polyclonal rabbit anti–human GR antibod-
ies (Affinity Bioreagents), anti-GR
 
a
 
 antibody (36), HIV-1
 
NL4-3
 
Vpr antiserum (National Institutes of Health AIDS Research and
Reference Reagent Program), or an anti-FLAG (M2) antibody
(Eastman Kodak Co.).
 
In Vitro Binding Assay.
 
35
 
S-labeled human GR
 
a
 
 were gener-
ated by in vitro translation and tested for interaction with GST-
Vpr, GST-VprL64A, or glutathione 
 
S
 
-transferase (GST) protein,
immobilized on glutathione-sepharose beads in the presence or
absence of 10
 
2
 
6
 
 M dexamethasone and/or 10
 
2
 
5
 
 M RU 486 in
buffer containing 50 mM Tris-HCl (pH 8.0), 50 mM NaCl, 1
mM EDTA, 0.1% NP-40, 10% glycerol, and 0.1 mg/ml BSA at
4
 
8
 
C for 1 h. After vigorous washing with the buffer, proteins
were eluted and separated on a 4–20% SDS-PAGE gel. Gels were
fixed and exposed on film. 
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Yeast Two Hybrid Assay.
 
Yeast strain EGY48 (Clontech) was
transformed with the 
 
lacZ
 
 reporter plasmid pSH18-34, pJG45-
GR
 
a
 
 coding sequence fused to B42-activation domain under the
control of the galactose-inducible promoter, and pLexA-Vpr cod-
ing for wild-type or mutant Vpr-LexA DNA-binding domain fu-
sion in pEG202 vector (32). The cells were grown to the early sta-
tionary phase in a selective medium with galactose to induce GR
 
a
 
fusion expression, and permeabilized with CHCl
 
3
 
-SDS treatment,
and the 
 
b
 
-galactosidase activity was measured in the cell suspension
using a colorimetric assay with ONPG as a substrate.
 
Coimmunoprecipitation of Vpr.
 
3 h before cell lysis, cells were
exposed to 10
 
2
 
6
 
 M dexamethasone and/or 10
 
2
 
5
 
 M RU 486. Cell
lysis and coimmunoprecipitation were carried out using lysis
buffer (50 mM Tris-HCl [pH 7.4], 400 mM NaCl, 0.2% NP-40,
Complete™ tablets 1 Tab/50 ml). Proteins were precipitated by
anti–human TFIID (TBP) antibody, anti–human TFIIB antibody
(Santa Cruz Biotechnology, Inc.), or by anti-GR
 
a
 
 antibody
bound to protein A Trisacryl (Pierce Chemical Co.). After blot-
ting on nitrocellulose membrane, FLAG-tagged Vprs were de-
tected by anti-FLAG (M2) antibody.
 
Statistical Analyses.
 
Statistical analysis was carried out by anal-
ysis of variance, followed by Student’s 
 
t
 
 test with Bonferroni cor-
rection for multiple comparisons.
 
Results
 
Vpr Enhances Glucocorticoid Response.
 
We first exam-
ined the effect of Vpr on the LTR promoter of mouse
mammary tumor virus (MMTV)-driven luciferase activity
in human T lymphoblastoma–derived CEM and Jurkat
cells, and human rhabdomyosarcoma–derived A204 and
HS729 cells. We cotransfected different amounts of a Vpr
expression vector, pCDNA3-VPR, with the dexametha-
sone-responsive plasmid pMMTV-luc (Fig. 1, A–D). Vpr
induced a 3.4-, 4.4-, 20-, and 4.5-fold increase of luciferase
activity in the dexamethasone-stimulated cell lines, respec-
tively, whereas it had minimal effects in the absence of dexa-
methasone. As A204 cells showed the highest increase of
luciferase activity, we conducted a dexamethasone titration
experiment in the presence or absence of pCDNA3-VPR
in this cell line (Fig. 1 E). The dose–response curve of the
MMTV promoter to dexamethasone was potently shifted
in the presence of Vpr, indicating that this protein potenti-
ates the glucocorticoid signal transduction pathway in a
fashion reminiscent of a classic coactivator (23).
To examine the dependence of the coactivator effect of
Vpr on the glucocorticoid ligand–receptor interaction, we
conducted several experiments in A204 cells using the GR
antagonist RU 486. The effect of Vpr on the MMTV pro-
moter was antagonized by RU 486 in a dose-dependent
fashion (Fig. 1 F). Vpr-enhanced luciferase activity was
completely abolished by 10
 
2
 
5
 
 M RU 486, and returned to
the levels seen in the absence of dexamethasone.
To show the dependency of the Vpr effect on the pres-
ence of GREs, we used three MMTV deletion mutants,
four GRE-containing promoter constructs, the simian vi-
rus 40 (SV40) and Rous sarcoma virus (RSV) promoters,
and the human 
 
b
 
-actin promoter, which contain no recog-
nizable GREs. Because the NF1 site is important for the
full activation of the MMTV promoter, we used promoter
constructs containing a synthetic NF1 site (Fig. 2 A). As
shown in Fig. 2, B and C, the coactivator effect of Vpr de-
pended on the presence of GREs. Decreasing the numbers
of GREs in the MMTV or in synthetic GRE promoters
was associated with diminishing Vpr coactivator activity.
Vpr had no or minimal effect on the synthetic promoters
not containing GRE sites and on the SV40, RSV, and
 
b
 
-actin promoters (data not shown). We also used CV-1
cells, which contain no functional GR, to show the re-
quirement of the GR for the coactivator effect of Vpr on
the MMTV promoter. Vpr-dependent activation could be
observed only when CV-1 cells were cotransfected with
the GR
 
a
 
 expression vector pRShGR
 
a
 
 (Fig. 2 D).
To rule out the possibility that Vpr might cause activa-
tion of the MMTV promoter by changing the levels of the
GR or the ratio of the GR 
 
a
 
 and 
 
b
 
 isoforms, we examined
the protein levels of the two isoforms of the GR in A204
cells (38). We enriched the transfected cell population up
to 90% by using Capture-Tec™ beads and examined the
effect of Vpr on the levels of the GR isoforms by Western
blot. As shown in Fig. 2 E, Vpr affected neither the levels
of these isoforms nor the isoform ratio in A204 cells.
We also examined the possibility that Vpr influenced the
translocation of the GR induced by dexamethasone in
A204 cells by using GFP-tagged hGR
 
a
 
 (GFP-GR
 
a
 
 [39,
40]). Vpr did not change the translocation rate or efficiency
of dexamethasone-activated GFP-GR
 
a
 
 (data not shown).
In addition, dexamethasone did not affect localization of
GFP-tagged Vpr at concentrations sufficient to translocate
the GFP-GR
 
a
 
 from the cytosol into the nucleus (data not
shown).
 
Vpr Interacts Directly with GR through the Coactivator Motif
LXXLL.
 
The recent discovery that cellular nuclear re-
ceptor coregulators contain one or more signature motifs
(LXXLL) through which they interact with nuclear hor-
mone receptors and exert their coregulator effects (41)
prompted examination of the Vpr sequence for such mo-
tifs. Since Vpr contains the sequence LQQLL at amino ac-
ids 64–68, a region of 
 
a
 
-helical secondary structure (42),
we examined the functional importance of this motif by
generating mutant Vpr proteins with disrupted sequences.
A mutant Vpr containing a leucine to alanine substitution
at amino acid 64 (VprL64A) failed to exert any coactivator
effect in our assays, and showed a concentration-dependent
dominant-negative effect on the wild-type Vpr (Fig. 3 A).
In contrast, VprL64A was fully functional in arresting cells
in G2/M phase of the cell cycle. A second point mutant,
VprR80A, showed the opposite phenotype; it had coactiva-
tion function similar to Vpr, but did not arrest cells in G2/M
(33). These results show that the glucocorticoid coactivator
activity of Vpr is distinct from its cell cycle arrest function
and requires an intact LXXLL domain.
To determine the specificity of the Vpr coactivator effect
on the glucocorticoid and other nuclear receptor signal
transduction pathways, we examined the effect of this pro-
tein on the progesterone, estrogen, and cAMP signal trans-
duction pathways in A204 cells. In the first two systems,
using the MMTV and the vitellogenin ERE-containing 
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promoters, respectively, we detected a small but significant
potentiation effect of Vpr by two- and fivefold, respec-
tively. In the third system, using a cAMP-responsive pro-
moter, Vpr showed no coactivator effect, even though the
GR and cAMP signal transduction pathways share p300/
CBP as a coactivator (25; Fig. 3 B). These findings suggest
that the coactivator effect of Vpr is exerted on the gluco-
corticoid as well as other nuclear receptor signal transduc-
tion pathways, and are in agreement with the effects re-
ported for other coactivators of steroid nuclear receptors
(25, 26, 41). We also tested the coactivator activity of HIV-2
and SIVmac239 Vpr and Vpx, since these proteins are evo-
lutionary related to HIV-1 Vpr (43), but do not have any
LXXLL coactivator signature motifs. None of these pro-
teins showed GR coactivator activity (data not shown).
To test the direct interaction of Vpr and GR, we used in
vitro–translated hGR
 
a
 
 and bacterially expressed GST-
tagged Vpr. Some binding of GR to GST-Vpr was de-
tected in the absence of dexamethasone, whereas binding
was increased in the presence of the steroid. In contrast,
GR did not bind to the mutant GST-VprL64A (Fig. 4 A).
RU 486 antagonized the dexamethasone-induced interac-
Figure 1. (A–D) Vpr potenti-
ates the transactivating effects of
dexamethasone on an MMTV-
LTR–driven luciferase reporter
gene in CEM (A), Jurkat (B),
A204 (C), and HS729 (D) cells
in a dose-dependent fashion.
Cells were transfected with dif-
ferent amounts of pCDNA3-
VPR and pMMTV-luc. Black
and white bars, mean 6 SEM
values obtained in the absence or
presence of 1027 M dexametha-
sone, respectively. *P , 0.001.
(E) Vpr produces a typical coac-
tivator shift of the dexametha-
sone dose–response curve. A204
cells were transfected with
pCDNA3-VPR or pCDNA3,
and pMMTV-luc. Each point
shows the mean 6 SEM value.
(F) The coactivator effect of Vpr
can be antagonized by the gluco-
corticoid antagonist RU 486 in a
dose-dependent fashion. A204
cells were transfected with differ-
ent amounts of pCDNA3-VPR
and pMMTV-luc. The indicated
amounts of dexamethasone and/
or RU 486 were added into the
culture medium 24 h after trans-
fection. Black bars, mean 6 SEM
values. 
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Figure 2. (A) MMTV (top) and synthetic GRE-containing (bottom) promoter constructs used to demonstrate dependence of Vpr effect on the pres-
ence of GREs. (B and C) Decreasing numbers of GREs in the MMTV (B) or synthetic GRE-containing (C) promoter were associated with decreasing
Vpr glucocorticoid coactivator activity. A204 cells were transfected with different amounts of pCDNA3-VPR and pMMTV-luc, pHH-luc, pM-luc,
pGRE2-E1B-CAT, pGRE2-NF1-E1B-CAT, pNF1-E1B-CAT, or pE1B-CAT. Black and white bars, mean 6 SEM values obtained in the absence or
presence of 1027 M dexamethasone, respectively. *P , 0.001. (D) The coactivator effect of Vpr depends on the presence of functional hGR in CV-1 cells.
Cells were transfected with different amounts of pCDNA3-VPR and pMMTV-luc in the presence (white bars) or absence (black bars) of pRShGRa.
For control, pRS-erbA21 was transfected instead of pRShGRa. Bars, mean 6 SEM values obtained in the presence of 1027 M dexamethasone. *P ,
0.001. (E) Detection of the GR isoforms a and b (a) or only a (b) in A204 cells transfected with pHook™-1 and either pCDNA3 (2) or pCDNA3-
VPR (1). Transfection-positive cells were collected by Capture-Tec™ beads. The GR (a and b) and the GRa were detected after blotting by using an-
tibodies that can recognize both the GR a and b (a), and specific antibodies for the GRa (b).
tion of GR to GST-Vpr. We also detected interaction of
GR with Vpr in the yeast two hybrid system (Fig. 4 B).
Wild-type Vpr and VprR80A, which retains coactivator
activity, interacted with the GR and induced b-galacto-
sidase activity, whereas the dominant-negative mutant
VprL64A produced no such effect, further supporting a di-
rect interaction between the two molecules in the cell.
Vpr Facilitates Formation of GR-containing Transcription
Complex through Multiple Contacts. It has been shown that
Vpr interacts with the RNA polymerase II ancillary factor56 A Viral Coactivator of the Glucocorticoid Receptor
TFIIB (44). The sequence necessary for this interaction was
mapped between amino acids 15 and 77. We examined the
coactivator function of an NH2-terminal deletion mutant
of Vpr using FLAG-Vpr(36–96), which contains a deletion
of the first 35 amino acids of Vpr and does not bind to
TFIIB. FLAG-Vpr(36–96) did not show any coactivator
effect on the MMTV promoter in A204 cells (Fig. 4 C). In
contrast, Vpr and FLAG-Vpr showed similar coactivator
Figure 3. (A) The coactivator effect of
Vpr depends on the presence of its LXXLL
signature motif. A mutant Vpr with a dis-
rupted coactivator motif lost its transcrip-
tion enhancing effect and gained dominant-
negative function. Black and white bars,
mean 6 SEM values obtained in the ab-
sence or presence of 1027 M dexametha-
sone, respectively. (B) The coactivator ef-
fect of Vpr is seen on nuclear receptor signal
pathways but not on the cAMP signal path-
way. A204 cells were transfected with GR,
ER, or PR expression vector and pM-
MTV-luc (for GR and PR) or ERE-tk-luc
(for ER) and treated with the corresponding
ligands. For analysis of the cAMP-induced
pathway, A204 cells were transfected with
pRc/RSV-CREB341 and p(271)SRIF-
CAT. To activate CREB, RSV-PKA
(white bars) or pRc/RSV (black bars, con-
trol) was also transfected. Bars, mean 6
SEM values obtained in the absence or
presence of 1027 M dexamethasone, proges-
terone, estradiol, and 0.5 mg/well of RSV-
PKA, respectively. *P , 0.001.
Figure 4. (A) Vpr can be directly associated with hGRa. In vitro–
translated hGRa and glutathione beads–immobilized GST-Vpr, GST-
VprL64A, or GST were incubated in the presence of 1026 M dexametha-
sone and/or 1025 M RU 486. Lane 1, 1/10 vol of 35S-labeled hGRa was
applied. (B) Interaction of Vpr with the GR in the yeast two hybrid assay.
Yeast cells were transformed with lacZ reporter plasmid pSH18-34,
pLexA-Vpr (wild-type or mutants L64A, R80A), and pJG45-GRa cod-
ing for the galactose-inducible GRa-activation domain fusion. LexA-Tat
was used as a negative control. b-galactosidase activity was stimulated by
Vpr but not VprL64A. b-galactosidase activity of yeast cells grown with
glucose rather than galactose was for all strains much less than the activity
produced by GR-LexA-Tat interaction viewed by us as a background value. (C) Coactivator function of Vpr, FLAG-Vpr, and FLAG-Vpr(36–96). A204
cells were transfected with different amounts of pCDNA3-VPR, pCMV-FLAG-VPR, or pCMV-FLAG-VPR(36–96), and pMMTV-luc. Each point
shows the mean 6 SEM values obtained in the presence of 1027 M dexamethasone. *P , 0.001. (D and E) Vpr, VprL64A, FLAG-Vpr, and FLAG-
Vpr(36–96) expressed and detected by Western blot in A204 cells using anti-Vpr or anti-FLAG (M2) antibody. A204 cells were transfected with
pCDNA3 (control), pCDNA3-VPR, or pCDNA3-VPRL64A, and Vpr was detected after immunoblotting by using HIV-1NL4-3 Vpr antiserum (D).
FLAG-Vpr or FLAG-Vpr(36–96) was detected by using anti-FLAG antibody (E).57 Kino et al.
activities on this promoter. Vpr, VprL64A, FLAG-Vpr, and
FLAG-Vpr(36–96) were expressed at similar levels and
could be detected in Western blots of extracts from A204
cells transfected with the corresponding plasmids (Fig. 4, D
and E). These results are consistent with the hypothesis
that the effect of Vpr as a coactivator depends also on the
presence of an intact TFIIB-binding domain.
We also studied the interactions of Vpr with GR and
components of the transcription complex in dexametha-
sone- and mock-treated pCMV-FLAG-VPR–transfected
cells by coimmunoprecipitations of cell extracts. As shown
in Fig. 5, FLAG-Vpr was coimmunoprecipitated by anti-
TFIID (TBP), anti-TFIIB, or anti-GR antibodies in dexa-
methasone-treated cells, suggesting that Vpr binds to com-
ponents of the transcription machinery and to the GR, as
part of the glucocorticoid-activated transcription initiation
complex (23). FLAG-VprL64A was coimmunoprecipitated
by anti-TFIIB antibody, suggesting that the TFIIB-binding
site of this mutant remains functional, whereas FLAG-
Vpr(36–96) was not precipitated by either GR, TFIID, or
TFIIB antibodies. Coprecipitation of FLAG-Vpr was not
efficient by TFIIB antibodies in the absence of dexametha-
sone, whereas it increased in its presence. FLAG-VprL64A
was similarly precipitated by TFIIB antibodies, but this did
not increase in the presence of dexamethasone. These re-
sults suggest that Vpr binds directly to TFIIB through the
NH2-terminal part of the molecule and to the GR through
the LXXLL coactivator domain. Binding to both factors
leads to enhanced incorporation of Vpr into a large tran-
scription complex also including other transcription factors
such as TFIID. The binding of the VprL64A mutant to
TFIIB but not to the GR may explain its transdominant
negative phenotype as competition of the mutant with wild-
type Vpr for the TFIIB-binding site. If Vpr becomes part of
a bigger transcription complex in the presence of dexa-
methasone, then it may be coprecipitated with antibodies
for other proteins known to be in the GR transcription
complex, such as the coregulators p300. In coimmuno-
precipitation experiments using lysate of FLAG-Vpr–trans-
fected A204 cells, Vpr and p300 were either weakly or
strongly coprecipitated by anti-FLAG antibody in the ab-
sence or presence of dexamethasone, respectively (data not
shown). This may reflect the presence of Vpr and p300 in
the same complex. Alternatively, it may indicate additional
contacts of Vpr with p300. It was recently suggested that
Vpr transactivation on the HIV promoter is mediated
through p300 (45). To study any potential interactions of
Vpr and p300, we compared the effects of transfected Vpr
and p300/CBP coregulators on the MMTV promoter
(Fig. 6 A). We also studied the interaction of Vpr with an-
other GR coactivator, steroid receptor coactivator (SRC)-1,
by cotransfecting pCDNA3-VPR with an SRC-1 expres-
sion vector. As shown in Fig. 6, A and B, Vpr potentiated
dexamethasone activity .20-fold. Vpr and p300 or SRC-1a
synergistically enhanced ligand-activated GR activity on
the MMTV promoter. No enhancement was observed in
the absence of glucocorticoid. Therefore, Vpr appears to
synergize with other coactivators in the activation of the
MMTV promoter.
Figure 5. Vpr can be precipitated with anti-TFIID (TBP), anti-TFIIB,
or anti-hGR antibodies in dexamethasone-treated A204 cells. A204 cells
were transfected with pCMV-FLAG-VPR, pCMV-FLAG-VPRL64A,
pCMV-FLAG-VPR(36–96), or pFLAG-CMV-2 (control). Cells were
treated with dexamethasone (Dex, 1026 M) and RU 486 (RU, 1025 M)
as indicated at the top, lysed in lysis buffer, and precipitated by using anti–
human TFIID (TBP) antibody, anti–human TFIIB antibody, or anti-
GRa antibody. FLAG-Vpr, FLAG-VprL64A, and FLAG-Vpr(36–96)
were detected after blotting by using anti-FLAG (M2) antibody. Lane 1
(marker), cell extracts from FLAG-Vpr–, FLAG-VprL64A–, and FLAG-
Vpr(36–96)–expressing cells before immunoprecipitation. In the pFLAG-
CMV2 (negative control) panel, FLAG-Vpr–containing extract was in-
cluded in lane 1 as marker.
Figure 6.  Vpr enhances the GR coactivation by p300 or SRC-1.
A204 cells were transfected with 1.5 mg/well of pMMTV-luc, 0.6 mg/
well of pCDNA3-VPR, 2.0 mg/well of CMVb-p300-CHA, or 2.0 mg/
well of pCR-SRC-1a as indicated. pCDNA3 (instead of pCDNA3-VPR
and pCMVb-p300-CHA) or pCR3.1 (instead of pCR-SRC-1a) was
cotransfected as needed to maintain the same amount of DNA. Black and
white bars, mean 6 SEM values obtained in the absence or presence of
1027 M dexamethasone, respectively.58 A Viral Coactivator of the Glucocorticoid Receptor
Discussion
Vpr stimulates HIV replication in lymphocytes and is
important for the efficient viral replication in macrophages
due to both transcriptional activation and its role in nuclear
targeting of the preintegration complex (5, 12–15). The
present work suggests that, in addition, Vpr may render
cells more sensitive to glucocorticoids. Though it is not
immediately clear what advantage such an activity may give
to the virus, this new effect may be of importance for AIDS
pathogenesis.
We found that in several lymphoid (CEM, Jurkat), rhab-
domyosarcoma (A204, HS729), and kidney (CV1) cell
lines Vpr dramatically increases the effect of glucocorticoids
on the MMTV promoter (Fig. 1). This effect of Vpr is me-
diated by binding to the GR through a helical part of the
molecule containing the LQQLL sequence; disruption of
the motif is detrimental for both GR binding and the tran-
scriptional effect of Vpr (Figs. 3 and 4). This region has
been shown to interact with transcription factor Sp1 (46).
Mutations in this region also decrease the nuclear localiza-
tion of Vpr (47). Similar motifs, LXXLL, were shown to be
involved in binding of several coactivator molecules to nu-
clear receptors (41). These findings suggest that Vpr is a vi-
rally encoded coactivator of the GR. Vpr also works as a
coactivator for other nuclear receptors, such as the progest-
erone and estrogen receptors, as would be expected from
the presence of a functional LXXLL motif. A previous re-
port has associated Vpr to the activated GR complex, pre-
sumably through interaction with a cytosolic protein,
named Rip-1 (16). Our results suggest that the observed as-
sociation to the activated GR complex is through a direct
interaction to GR.
Classical nuclear receptor coactivators, like SRC-1 and
CBP/p300, were shown to interact with the receptors in the
presence of the appropriate ligand as well as with general
transcription factors, components of the RNA polymerase II
complex (29, 48). They also possess histone acetyltransferase
activity that may overcome the inhibitory effect of chromatin
on gene expression, leading to efficient transcription (28, 30).
Coprecipitation experiments (Fig. 5) showed that in the
presence of glucocorticoid Vpr became associated not only
with the GR, but also with TFIIB and TFIID, consistent
with its incorporation into a stable transcription initiation
complex, reminiscent of other nuclear receptor coactiva-
tors. Notably, mutant VprL64A, which is unable to en-
hance the glucocorticoid response, was excluded from such
a complex, but was still able to bind to TFIIB. This obser-
vation is consistent with the reported ability of the NH2-
terminal part of Vpr to interact with TFIIB (44) and may
explain the dominant-negative phenotype of the L64A
mutation that disrupts GR binding but retains the ability to
bind, and thus block, a general transcription factor.
These results suggest that Vpr functions by bridging the
ligand-bound nuclear receptor and general transcription
factors, resulting in the stabilization of the transcription
preinitiation complex. It is also highly probable that Vpr
cooperates with and enhances the activity of other coacti-
vators, the same way coactivators cooperate with each
other. We found synergistic effects of Vpr with both p300
and SRC-1 on the MMTV promoter (Fig. 6). The simplest
interpretation of these results is that each coactivator, in-
cluding Vpr, contributes to the efficiency and stability of
the transcription initiation complex (Fig. 7).
The relation of nuclear receptor coactivator activity of
Vpr described in this work to previously described tran-
scriptional effects of this HIV protein is not clear. The
stimulatory effect of Vpr on several promoters, including
HIV-1 LTR, correlates with Vpr’s ability to block cell cy-
cle. It was proposed that G2 arrest in T cells was sufficient
to enhance LTR transcription (5). The ability of Vpr mu-
tants to arrest dividing cells correlated also with transcrip-
tion stimulation in nondividing macrophages, suggesting
that cell cycle arrest is not a prerequisite for transcriptional
activation by Vpr (15). In either case, it appears that the
Vpr effect on nuclear receptors is distinct from HIV-1
LTR activation and cell cycle arrest. Our mutational analy-
sis showed that there is no correlation between the ability
of Vpr to stimulate glucocorticoid response and its cell cy-
cle–blocking activity. VprL64A, a mutant unable to acti-
vate GR, was proficient in the cell cycle arrest, whereas
VprR80A, known to be inactive in the arrest (49), was
fully able to activate glucocorticoid response (33).
The contribution of the glucocorticoid coactivator effect
of Vpr on the replication of HIV-1 remains to be defined.
The reported effects of glucocorticoids on HIV-1 expres-
sion have been controversial and both mildly stimulatory
and inhibitory (5, 16, 50–53). However, there is a role for
the Vpr coactivator activity in the pathophysiology of
HIV-1 infection. Patients with AIDS have clinical manifes-
Figure 7. A model of the involvement of Vpr in glucocorticoid-depen-
dent activation of transcription. Vpr enhances the glucocorticoid response
by direct association with components of the glucocorticoid-induced
transcription initiation complex, including the GR itself and TFIIB. In-
teractions with p300/CBP and SRC-1 are also possible. This function of
Vpr is similar to that of other known mammalian coactivators.59 Kino et al.
tations compatible with glucocorticoid hypersensitivity, re-
flected in severe immune suppression and profound
myopathy and muscle wasting, all recognized effects of
chronically elevated levels of glucocorticoids. Thus, the
glucocorticoid coactivator actions of Vpr may contribute,
along with actions of other viral proteins, to the develop-
ment of HIV-1–associated pathologies. Furthermore, Vpr
may mimic glucocorticoid effects on apoptosis and on im-
mune system suppression through induction of IkB tran-
scription (54). The role of HIV-1 on muscle wasting can-
not be explained by direct effects of the virus. However,
Vpr can be detected outside of infected cells and in the
plasma of HIV-1–infected patients (17, 18). Like Tat, Vpr
appears also to affect uninfected cells in a paracrine or en-
docrine fashion (17, 18, 55, 56). If Vpr contributes to in-
creased tissue sensitivity to glucocorticoids, our data suggest
a role for steroid hormone receptor antagonists, such as
RU 486, or Vpr antagonists in the treatment of HIV-1 dis-
ease, even in the absence of hypercortisolism.
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